IP Library Granted Patent US 9,446,143
Granted Patent B2
US 9,446,143 · App. 14/139,293 · Granted Sep 20, 2016

Influenza antigen delivery vectors and constructs

Inventors: Dominique Bonnet (Geispolsheim, FR); Carlton B. Brown (Santa Cruz la Laguna, GT); Bertrand Victor Gilbert Georges (London, GB); Philip J. Sizer (Helsby, GB)
Assignee: ALTIMMUNE UK LIMITED
A61K47/4833A61K39/12A61K39/145A61K39/21A61K39/385A61K47/48023A61K47/48176C07K14/005A61K2039/54A61K2039/55511A61K2039/60A61K2039/6018A61K2039/6031C12N2740/16122C12N2740/16134C12N2760/16034C12N2760/16122C12N2760/16222C12N2760/16322
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,446,143
App. No.
14/139,293
Granted
Sep 20, 2016
Kind
B2
Abstract

The present invention relates to fluorocarbon vectors for the delivery of influenza antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-influenza antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals, including humans.

Claims (10)

1. A pharmaceutical composition for intracellular delivery of an antigen, the composition comprising an antigenic influenza peptide sequence covalently attached to a vector construct, wherein the vector construct comprises a chain comprising from 3 to 30 carbon atoms at least one of which is substituted with a fluorine, chlorine, bromine, or iodine and the antigenic influenza peptide sequence is up to 40 amino acids in length and comprises the amino acid sequence of any one of SEQ ID NOs: 1-65.

2. The composition of claim 1 , wherein the vector is of structure C m F n —C y H x -(Sp)-R, wherein m=3 to 30, n<=2m+1, y=0 to 15, x<=2y, (m+y)=3to 30, Sp is an optional chemical spacer moiety and R is the influenza peptide sequence.

3. The composition of claim 1 , wherein the composition comprises 5, 6, 7, or 8 of the antigenic influenza peptide sequences each covalently attached to a vector construct.

4. The composition of claim 1 , wherein the influenza peptide sequences are selected from the group consisting of SEQ ID Nos. 1, 4, 17, 18, 19, 20, 32 and 35.

5. The composition of claim 1 , further comprising one or more pharmaceutically acceptable carriers, excipients, diluents, or adjuvants.

6. The composition of claim 1 , formulated for parenteral, oral, ocular, rectal, nasal, transdermal, topical, or vaginal administration.

7. The composition of claim 1 , wherein the composition is in the form of a liquid, emulsion, solid, aerosol, or gas.

8. A method of stimulating an immune response, comprising administering the composition of claim 1 to an animal.

9. The method of claim 8 , wherein the animal is a mammal, a bird or a human.

10. A method of preparing a prophylactic or therapeutic pharmaceutical composition comprising combining the composition of claim 1 , with one or more pharmaceutically acceptable carriers, excipients, diluents, or adjuvants.

Assignments (3)
CHANGE OF NAME Recorded Nov 10, 2015
From: VAXIN UK LIMITED
To: ALTIMMUNE UK LIMITED
Reel/Frame 037083/0588 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2015
From: BONNET, DOMINIQUE; SIZER, PHILIP J.; BROWN, CARLTON B.; GEORGES, BERTRAND
To: IMMUNE TARGETING SYSTEMS LTD.
Reel/Frame 036975/0326 →
CHANGE OF NAME Recorded Nov 6, 2015
From: IMMUNE TARGETING SYSTEMS (ITS) LIMITED
To: VAXIN UK LIMITED
Reel/Frame 037058/0855 →
Priority Claims (1)
GB 0716992.3 · Aug 31, 2007 · national
Continuity (3)
Continuation 12201894 · Aug 29, 2008
Provisional Application 60969481 · Aug 31, 2007
Related Publication 20140234356A1 · Aug 21, 2014